Clinical trial
Consequence of Lifetime Isolated Growth Hormone Deficiency
NCT00149708 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00149708 |
|---|---|
| Title | Consequence of Lifetime Isolated Growth Hormone Deficiency |
| Official title | Consequence of Lifetime Isolated Growth Hormone Deficiency |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Growth Hormone Deficiency |
| Intervention type | Drug |
| Interventions | growth hormone administration for 6 months |
| Enrollment | 400 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 8, 2005 |
| Last update posted | Jun 15, 2010 |
| Countries | Brazil |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: